BCRP及MDR1在非霍奇金淋巴瘤接受化疗患者的表达及临床意义  

The gene expression and its clinical significance of breast cancer resistance protein (BCRP) and MDR1 in patients with non-hodgkin lymphoma

作　　者：钱素英[1] 毛联钢[1] 吴宁宁[1] 方治[1] 陈亚敏[1] 童向民[2] 李克强[1] 夏兆雄[1] 

机构地区：[1]宁波市第二医院,浙江宁波315010 [2]浙江大学医学院附属第一医院,浙江杭州310003

出　　处：《现代实用医学》2009年第5期427-428,431,F0002,共4页Modern Practical Medicine

基　　金：宁波市卫生局项目;编号2002036

摘　　要：目的探讨非霍奇金淋巴瘤(NHL)患者乳腺癌耐药蛋白(BCRP)及多药耐药相关蛋白1(MRP1)的表达及临床意义。方法采用RT-PCR法检测66例NHL患者新鲜淋巴组织标本BCRP及MDR1的表达。结果66例NHL患者BCRP阳性率45.5%,MDR1阳性率59.1%,BCRP+MDR1+、BCRP+MDR1-、BCRP-MDR1+、BCRP-MDR1-四组化疗效果差异有统计学意义(<0.05)。结论BCRP及MDR1表达率高,是化疗敏感性差的重要原因。Objective To investigate the relationship between the expression of BCRP and MDRI gene in patients with Non-Hodgkin lymphoma. Methods The expression of BCRP and MDR1 gene in 66 NHL cases were examed by reverse transcriptase polymerase chain reaction（RT-PCR）. Results The positive ratio of BCRP gene was 45.5% and MDR1 gene was 59.1% in 66 NHL. The response of treatment were different among the group of BCRP^＋MDR1^＋, BCRP^＋ MDR1^-, BCRP^- MDR1^＋ and BCRP MDRI^-（P 〈 0.05）. Conclusion Maybe the poor response of therapy has a close relation with the high expression of BCRP and MDR1.

关 键 词：淋巴瘤 非霍奇金 抗肿瘤联合化疗方案 乳腺癌耐药蛋白 多药耐药相关蛋白1 

分 类 号：R733.4[医药卫生—肿瘤] R73-361[医药卫生—临床医学]